Category: News

HAlllo!
  • EvlaBio raises €21 million Seed Funding

    EvlaBio raises €21 million Seed Funding to Develop a Monoclonal Antibody for the Treatment of Left Ventricular Hypertrophy in the Setting of Chronic Kidney Disease.

    • EvlaBio secures €21 million Seed Funding to complete preclinical development and progress towards IND-enabling studies.
    • The financing round is led by Kurma Partners as well as AdBio Partners, Boehringer Ingelheim Venture Fund, NRW.Venture (NRW.BANK) and HTGF.
    • EvlaBio’s lead program consists of a first-in-class therapeutic monoclonal antibody treatment of left ventricular hypertrophy in the setting of chronic kidney disease with the potential to transform outcomes for millions of patients.

    EvlaBio, a life science startup pioneering innovative therapies for the treatment of Left Ventricular Hypertrophy (LVH) in the setting of Chronic Kidney Disease (CKD), announced today the successful closing of its seed funding round, one of the largest seed rounds closed in Germany to date. The financing will support the advancement of EvlaBio’s lead program, a first-in-class therapeutic monoclonal antibody targeting specifically the FGF23/FGFR4 signaling in the setting of CKD, one of the key drivers for LVH, which can lead to heart failure.

    Founded with a mission to address high unmet medical need in the cardiorenal field, EvlaBio is developing a targeted treatment for patients suffering from CKD with limited therapeutic options. The company’s lead asset is a novel monoclonal antibody designed to inhibit the pathological FGF23/ FGFR4 cardiac signaling axis — a critical driver of cardiac remodeling in patients with CKD.

    “Despite recent advances, the clinical need in LVH in the context of CKD remains significant, with high prevalence and substantial negative impact on patients’ outcomes. Even with improved management of hypertension and anemia, LVH often persists or even progresses in CKD patients”, said Wenzel von der Heydte, CEO & Co- Founder of EvlaBio. “EvlaBio’s approach is unique in its ability to directly target a key pathway on the cardiomyocyte level. This new therapeutic avenue has the potential to improve lives of millions of patients.”

    The program originates from Lead Discovery Center GmbH (LDC), a company established in 2008 by the technology transfer organization Max Planck Innovation, where it has been developed in collaboration with KHAN Technology Transfer Fund I GmbH & Co KG (KHAN-I).

    “Blocking cardiac FGF23/FGFR4 overdrive has the strong potential to become a very promising treatment option for millions of patients facing a high risk of cardiac remodeling and progression to heart failure in CKD,” said Thomas Kirmeier, COO & Co- Founder of EvlaBio. “Heart failure is a leading cause of morbidity and mortality in this patient population and our therapeutic approach offers a promising strategy to modify disease progression at its root.”

    The seed round was led by Kurma Partners, AdBio Partners, Boehringer Ingelheim Venture Fund, NRW.Venture (NRW.BANK) and HTGF, and will enable EvlaBio to complete preclinical development and progress towards IND-enabling studies.

    Hadrien Bouchez, Partner at Kurma Partners added: ”We’re excited to partner with EvlaBio as they advance their groundbreaking approach targeting the FGFR4/FGF23 pathway. The team’s deep scientific expertise and compelling preclinical data position them to address cardiac hypertrophy in CKD patients—a significant unmet medical need affecting millions worldwide. Their differentiated approach offers meaningful advantages over existing therapeutic options. This investment reflects our commitment to supporting innovative companies poised to transform patient outcomes in areas of high unmet need”.

    Clément Bertholet, Managing Partner at AdBio Partners added: ”This investment in EvlaBio, the first one for AdBio Partners in Germany, is driven by the key features of the product developed by the team to target the well-known FGFR4/FGF23 pathway. We are thrilled to support the company through its development to ultimately bring innovative treatments to patients in need”.

    Marek Kozlowski, Senior Investment Director at NRW.BANK, commented: “The FGFR4/FGF23 axis is a very well-validated target pathway, yet its clinical potential remains unrealized. EvlaBio’s research and development program can finally change this. With a substantial seed funding from NRW.Venture and this high-quality syndicate, EvlaBio is wellpositioned to advance the development of the lead candidate to the next value inflection point.“


    About EvlaBio
    EvlaBio is a life science company focused on developing first-in-class therapeutics for cardiovascular and cardiorenal diseases. Its lead program targets the FGFR4/FGF23 signaling axis, a critical driver of cardiac remodeling in chronic kidney disease. By advancing novel mechanisms grounded in strong translational science, EvlaBio aims to redefine treatment paradigms for CKD patients with high unmet medical need.  


    About Kurma Partners
    Kurma Partners is a key European player in the financing of innovation in Healthcare and Biotechnology, from pre-seed to growth capital, in particular through its funds Kurma Biofund I, II, III, IV, Kurma Growth, Kurma Diagnostics and Kurma Diagnostics 2, as well as the links the company has forged with a network of prestigious research institutes and hospitals. Kurma Partners was founded in July 2009 and is based in Paris and in Munich. Learn more at www.kurmapartners.com


    About AdBio Partners
    AdBio Partners is a European VC firm based in Paris and Barcelona that invests mainly in therapeutics-oriented projects. AdBio partners’ unique strategy combines early-stage investments in promising companies and strong entrepreneurial support to strengthen the company’s growth. Created in 2016, AdBio Partners has made 28 European investments from two seed-funds. Those companies have raised more than €1Bn additional capital from international syndicates and strategics. Learn more at www.adbio.partners


    About Boehringer Ingelheim Venture Fund
    The Boehringer Ingelheim Venture Fund (BIVF), established in 2010, is dedicated to investing in groundbreaking biotechnology companies that are at the forefront of therapeutic and digital innovations, aiming to advance biomedical research. With a commitment to revolutionizing the standard of care, the BIVF fosters long-term partnerships with scientists and entrepreneurs. The BIVF’s focus is on nurturing disease-modifying therapeutic concepts and facilitating their clinical application. The BIVF prioritizes the translation of first-in-class concepts that address significant medical needs in fields such as oncology, immunology, regenerative medicine, neurodegeneration, infectious diseases, and digital health technologies. These innovative concepts often encompass novel platform technologies designed to tackle targets and diseases that were previously considered untreatable.
    With a fund volume of EUR 350 million, the BIVF operates as an evergreen fund, continually reinvesting to fuel its mission. The partners of the BIVF gain from the fund’s deep expertise in drug discovery & development, translational science, and management, along with access to a network of experts within the Boehringer Ingelheim organization. Currently, the BIVF supports a diverse portfolio of over 40 companies, leveraging its extensive experience to drive progress in healthcare.  

    For additional information, please visit boehringer-ingelheim-venture.com.


    About NRW.Venture (NRW.BANK)
    NRW.Venture is the venture capital fund of NRW.BANK, located in Düsseldorf. Together with private-sector investors, NRW.Venture invests up to 15 million euros of equity in young and innovative start-ups over several financing rounds, with NRW.BANK taking a minority stake with a term of three to seven years. But the Bank not only provides capital – an experienced team is the key to joint success. Since the inception of its venture capital fund in 2005, NRW.BANK has invested in over 30 companies within the life sciences and healthcare sectors, spanning biotech, medtech, diagnostics, lab tools, and digital health. The investment professionals at NRW.Venture bring many years of venture capital experience, often enhanced by backgrounds in technology and start-ups, leveraging their expertise and networks to maximise the success potential of start-ups.


    About HTGF – High-Tech Gründerfonds 
    HTGF is one of the leading and most active early-stage investors in Germany and Europe, financing startups in the fields of Deep Tech, Industrial Tech, Climate Tech, Digital Tech, Life Sciences and Chemistry. With its experienced investment team, HTGF supports startups in all phases of their development into international market leaders. HTGF invests in pre-seed and seed phases and can participate significantly in later-stage financing rounds. Since its inception in 2005, HTGF has financed more than 780 startups and achieved almost 200 successful exits. HTGF has a fund volume of over 2 billion euros. 

    Fund investors in the public-private partnership include the Federal Ministry for Economic Affairs and Energy, KfW Capital as well as 45 companies and family offices. For more information, please visit HTGF.de or follow us on LinkedIn.   


    About LDC
    Lead Discovery Center GmbH (LDC) was established in 2008 by the technology transfer organization Max Planck Innovation, as a novel approach to capitalize on the potential of excellent basic research for the discovery of new therapies for diseases with high medical need. LDC takes on promising earlystage projects from academia and transforms them into innovative pharmaceutical leads and antibodies that reach initial proof-of-concept in animals as well as candidate nomination. In close collaboration with high-profile partners from research and industry, LDC is building a strong and growing portfolio of small molecule and antibody leads with exceptional medical and commercial potential.  

    LDC sustains a long-term partnership with the Max Planck Society and its institutes as well as with KHAN-I and KHAN-II, and has formed alliances with AstraZeneca, Bayer, Boehringer Ingelheim, Merck KGaA, Daiichi Sankyo, Qurient, InvIOS, Novo Nordisk, Cumulus Oncology, Nodus Oncology, JT Pharmaceuticals, KinSea Lead Discovery AS, HLB Pharma, the Helmholtz Center for Infection Research, e.g. In addition, LDC also works with leading translational drug discovery centers and with various investors to provide its assets for company creation.

    Further information at: www.lead-discovery.de
    Contact: pr@lead-discovery.de


    About KHAN-I
    KHAN Technology Transfer Fund I GmbH & Co KG (KHAN-I) is an early-stage life sciences venture fund with € 70 million under management. Their mission is to create value through cooperative drug development partnerships with academic innovators in Europe. KHAN-I received an investment from the European Investment Fund (EIF) with the support of InnovFin Equity, and with the financial backing of the European Union under Horizon 2020 Financial Instruments and the European Fund for Strategic Investments (EFSI) under the Investment Plan for Europe.  KHAN-I is also supported by Austria Wirtschaftsservice GmbH Max Planck Foundation, and Thyssen’sche Handelsgesellschaft mbH. In addition, KHAN-I sustains a preferred partnership with the Max Planck Society (Max-Planck-Gesellschaft e.V.).

    Further information at: www.khanu.de

  • Carelane sets new standards for clinical research with AI-driven, end-to-end platform 

    Carelane sets new standards for clinical research with AI-driven, end-to-end platform 

    • Carelane increases speed and efficiency, and improves the quality of clinical trials with an AI-powered clinical research hub  
    • Significant time and cost savings: cost reduction of up to 80 percent  
    • Seed funding of EUR 2.6 million led by Vorwerk Ventures 

    As clinical studies are always increasing in complexity, research institutions’ software solutions remain fragmented and outdated. Carelane has developed an end-to-end platform that integrates all phases of a study, from protocol development to data analysis. Their innovative approach combines the latest AI technology with a structured digital protocol based on FHIR standards. More than 130 research sites across six continents already rely on Carelane’s software solution. “We’ve engineered a cutting-edge platform that meets the demands of intricate clinical studies and increases efficiency through AI and automation. Workflows are simplified, clinical trials can be completed faster, and the overall quality is elevated,” explains CEO Yannick Boerner

    The research tool of tomorrow 

    More efficient, cheaper, and higher-quality clinical trials – Carelane achieves this via:  

    • End-to-end platform: Carelane covers all steps from protocol development to evaluation, with seamless integration promoting efficient collaboration. This eliminates traditional bottlenecks by linking all stakeholders to a shared, real-time infrastructure.  
    • Resource efficiency: Because there are fewer manual processes, the burden on research sites is eased, leading to cost savings of up to 80 percent. And because of AI-driven assistance and automation, research teams save time on study setup, site onboarding and participant enrolment.  
    • Increased data quality: Standardized data collection, real-time monitoring with built in AI-agents, and automated validation ensure reliable data and reduce protocol amendments. 

    A new era for study planning and execution 

    Carelane supports research teams from the earliest planning phases. The platform’s integrated AI-agents assist in decision-making, planning, and automating complex processes. The structured digital protocol based on FHIR standards ensures improved data quality. It guarantees synchronization with downstream systems and enables source data capture through the ingestion of electronic health records (EHRs). Researchers and study teams can now seamlessly move from creating their digitized protocol to configuring and deploying integrated modules, including EDC, eConsent, eCOA, EHR/EMR integrations, tokenization, and participant management. 

    Future-proof research – collaborative and integrated 

    All stakeholders – from sponsors to CROs to research sites – should be able to collaborate in real-time – Carelane makes this a reality. Stakeholders can now manage processes more effectively, and eliminate people silos and data silos. The tool brings all stakeholders together in a single digital infrastructure for the first time. Instead of separate tools, users can now rely on just one platform for medical writing, clinical strategy, operations, and data management. Carelane’s collaborative platform revolutionizes clinical research – a vision that found broad support in the investor community. 

    Successful seed funding completed 

    After a successful pre-seed phase, Carelane secured 2.6 million euros in April 2025 during a seed funding round led by Vorwerk Ventures, with additional participation from High-Tech Gründerfonds (HTGF) and private investors. “Carelane is revolutionizing how clinical research is done. We are impressed by how quickly they have gained traction. This rapid adoption shows the value that their AI-driven, end-to-end platform brings to a sector which is hungry for more efficient and higher-quality research. We are excited to support the company in its course of growth,” says Sascha Günther, partner of Vorwerk Ventures. The capital will be used to expand sales and customer support, scale technological infrastructure, and drive the further development of AI functions. 


    About Carelane 
    Carelane is re-imagining how clinical research gets done – with AI-powered technology that breaks down both data silos and people silos. Carelane is the AI-native clinical-research hub combining protocol authoring, EDC, eCOA, eConsent, participant management, tokenization, data analysis, document management and EMR/EHR connectivity in a single collaborative workspace. Every stakeholder—Medical Writing, Clinical Strategy, Clinical Operations, Data Management, Regulatory, Market Access, Sites, CROs, Sponsors and participants—works from a single source of truth without bouncing between disconnected point solutions. 

    For more information: www.carelane.io 

    About HTGF – High-Tech Gründerfonds
    HTGF is one of the leading and most active early-stage investors in Germany and Europe, financing startups in the fields of Deep Tech, Industrial Tech, Climate Tech, Digital Tech, Life Sciences and Chemistry. With its experienced investment team, HTGF supports startups in all phases of their development into international market leaders. HTGF invests in pre-seed and seed phases and can participate significantly in later-stage financing rounds. Since its inception in 2005, HTGF has financed more than 780 startups and achieved almost 200 successful exits. HTGF has a fund volume of over 2 billion euros. 

    Fund investors in the public-private partnership include the Federal Ministry for Economic Affairs and Energy, KfW Capital as well as 45 companies and family offices. For more information, please visit HTGF.de or follow us on LinkedIn.   

    Media contact
    High-Tech Gründerfonds Management GmbH 
    Tobias Jacob, Senior Marketing & Communications Manager  
    T.: +49 228 – 82300 – 121 
    t.jacob@htgf.de

  • Biograil raises EUR 8.5 million to support clinical testing of oral therapeuticdelivery device

    Biograil raises EUR 8.5 million to support clinical testing of oral therapeuticdelivery device

    Biograil raises EUR 8.5 million to support clinical testing of oral therapeutic delivery device

    Biograil ApS, a Copenhagen based biotech company developing a unique oral device for delivery of therapeutics that would otherwise have to be injected, announced a first closing of EUR 8.5 million of a financing round led by Verve Ventures. Existing investors including HTGF and Megatrend participated. Acondis GmbH joined the syndicate as a new investor. Follow-up closings with additional funds are planned for later in 2025.

    Steffen Wagner, co-founder and co-CEO of Verve Ventures, will join Biograil’s Board of Directors. Wagner’s financial and investment expertise will be a valuable addition to the director group. The additional funds will support the preparation activities for the planned phase 1 clinical testing of BIONDD®.

    Biograil CEO Karsten Lindhardt said: “We are pleased to secure robust financing for Biograil by a strong syndicate of investors in a difficult financing landscape. Biograil has made great strides in advancing the BIONDD® technology, completing outstanding and extensive preclinical studies proving the oral delivery of many injectable compounds with comparable bioavailability to subcutaneous injections. Biograil looks forward to further developing the BIONDD® technology and completing the preparation for clinical studies bringing significant value to the platform.”

    Karsten Lindhardt, Biograil CEO (Photo: Biograil)

    Verve CEO, Steffen Wagner commented: “Verve Ventures is extremely happy to participate and lead this important Biograil financing. Biograil’s BIONDD® technology has matured significantly, is applicable to a broad range of opportunities and addresses a multi-billion-dollar market. I look forward to working closely with the Biograil team as Biograil moves to the next stage of development.”


    About Biograil ApS
    Biograil is a Copenhagen based biotech company developing pharmaceutical products based upon the BIONDD® device contained in a standard size, double zero or single zero, capsule able to deliver active therapeutics into the stomach mucosal wall to be effectively distributed in the human body. Such therapeutics can be currently marketed products, including multi-billion-dollar injectable pharmaceuticals or new chemical entities that cannot otherwise be delivered orally. The Biograil device uses a novel mechanism to facilitate the delivery of active substances, i.e., biologics, efficiently into the stomach wall utilizing a proprietary platform technology manufactured by injection molding. The team behind Biograil is a combination of seasoned entrepreneurs with extensive experience in creating successful biotech companies as well as R&D executives behind the world’s first injection molded oral tablet approved by the FDA.
    Biograil has collaborations with Eli Lilly & Co and CSL Behring. The Biograil investor syndicate includes Megatrend Invest, Verve Ventures, High-Tech Gründerfonds, Eli Lilly and Co., Sanner Ventures, Evonik Venture Capital, Acondis GmbH and Roquette Ventures.

    About Verve Ventures
    Verve Ventures is one of Europe’s most active venture capital firms, focusing on deep tech. Founded in 2010 in Switzerland, Verve backs outstanding startups based on scientific excellence from the Seed stage onward. It has an active portfolio of over 150 companies and has achieved over 20 successful exits. Through Verve Ventures, startups get access to an extensive network of sophisticated private and institutional investors who actively help them succeed.

    About HTGF – High-Tech Gründerfonds 
    HTGF is one of the leading and most active early-stage investors in Germany and Europe, financing start-ups in the fields of Deep Tech, Industrial Tech, Climate Tech, Digital Tech, Life Sciences and Chemistry. With its experienced investment team, HTGF supports start-ups in all phases of their development into international market leaders. HTGF invests in pre-seed and seed phases and can participate significantly in later-stage financing rounds. Across its funds, HTGF has over 2 billion euros under management. Since its inception in 2005, HTGF has financed more than 770 start-ups and achieved almost 200 successful exits.  
    Fund investors in the public-private partnership include the Federal Ministry for Economic Affairs and Energy, KfW Capital as well as 45 companies and family offices.  
    For more information, please visit HTGF.de or follow us on LinkedIn.   

    Media Contact 
    High-Tech Gründerfonds Management GmbH 
    Tobias Jacob, Senior Marketing & Communications Manager  
    T.: +49 228 – 82300 – 121
    t.jacob@htgf.de   

  • Steuerboard Secures €725K Pre-Seed Round

    Steuerboard Secures €725K Pre-Seed Round

    Steuerboard Secures €725K Pre-Seed Round to Revolutionize Tax Workflows with AI 

    Steuerboard, the Düsseldorf‑based B2B SaaS platform rethinking tax workflows, today announced it has raised €725,000 in a pre-seed financing round led by High‑Tech Gründerfonds (HTGF), with participation from SuperAngels Fund and serial entrepreneur Roland Fassauer.

    The funding will accelerate product development and deepen market expansion across Germany. 

    Jakob Brandt and Matyas Heins, founders of Steuerboard (Photo: Steuerboard)

    Tackling Tax Industry Bottlenecks with AI 
    Founded in July 2023 by Matyas Heins (29) and Jakob Brandt (28), Steuerboard tackles the specialist‑staff shortage in tax advisory firms by eliminating email “ping‑pong,” improving transparency and automating routine data processes. Its AI‑native platform integrates seamlessly with existing systems to deliver agentic AI to proactively handle routine decisions and workflows. 

    Tapping Into a €1.3B Opportunity in Germany’s Tax Tech Market 
    The global tax software market was valued at USD 18.5 billion in 2023 and is projected to grow at a 10 % CAGR through 2030 (source: marknteladvisors.com). In Europe, the tax management software segment alone generated USD 4.72 billion (€4.34 billion) in 2023 (source: Grand View Research). Germany is the largest national market—accounting for roughly 30 % of the European total—implying an annual opportunity of over €1.3 billion for solutions like Steuerboard. 

    “We’re thrilled to partner with HTGF and our angel investors to scale Steuerboard’s AI‑powered automations,” said Matyas Heins, Co‑Founder. “This investment will enable us to rapidly enhance features that save tax offices time and deliver a seamless, transparent experience for their clients.” 

    “Steuerboard’s AI‑first platform addresses a critical need in the tax advisory sector,” said Christian Arndt, Principal at HTGF. “We believe their centralized data approach will set a new standard for efficiency and collaboration.” 

    Rapid Adoption Fuels Ambitious Growth Roadmap 
    Since launch, Steuerboard has onboarded nearly 100 tax offices—ranging from boutique firms to larger practices with hundreds of employees—and supports thousands of businesses each month. Their rapid adoption underscores strong demand for digital, AI‑driven collaboration in Germany’s tax industry.  

     With the new capital, Steuerboard will expand its engineering and customer‑success teams, accelerate development of advanced agentic AI workflows, and broaden its sales footprint across the DACH region. Over the next 24 months, the company aims to redefine automation in the tax ecosystem by embedding intelligent, end‑to‑end workflows that anticipate advisor and client needs. 


    About Steuerboard 
    Founded in July 2023 and headquartered in Düsseldorf, Steuerboard is a B2B SaaS company on a mission to rethink tax workflows. Its AI‑native platform centralizes data, automates routine tasks, and provides transparent collaboration between tax advisors (“Steuerberater”) and their clients (“Mandanten”), helping firms overcome specialist‑staff shortages and boosting customer experience. 

    Press Contact: 
    pr@steuerboard.net 
    www.steuerboard.net 

    About superangels 
    Superangels is a business angel matching fund founded by experienced entrepreneurs Franzi Majer, Alexander Brand & Florian Gottschaller, sharing their passion for early-stage tech startups. What began as friends co-investing has grown into an early stage tech fund, investing with a curated network of expert business angels – the superangels. 

    Superangels matches investments in pre-seed and seed-stage startups across sectors like Climate Tech, AI, Deep Tech, and SaaS. By combining financial strength with deep industry insights, superangels enhances deal flow, strengthens startups, and improves outcomes for all stakeholders. 

    Driven by a belief in transformative entrepreneurship, superangels backs exceptional founders building the next generation of global tech champions. With already 75 investments in its portfolio, superangels is one the most active early stage funds in Europe. 

    Learn more at super-angels.eu or follow us on LinkedIn

    About HTGF – High-Tech Gründerfonds 
    HTGF is one of the leading and most active early-stage investors in Germany and Europe, financing startups in the fields of Deep Tech, Industrial Tech, Climate Tech, Digital Tech, Life Sciences and Chemistry. With its experienced investment team, HTGF supports startups in all phases of their development into international market leaders. HTGF invests in pre-seed and seed phases and can participate significantly in later-stage financing rounds. Since its inception in 2005, HTGF has financed more than 780 startups and achieved almost 200 successful exits. HTGF has a fund volume of over 2 billion euros. 

    Fund investors in the public-private partnership include the Federal Ministry for Economic Affairs and Energy, KfW Capital as well as 45 companies and family offices. For more information, please visit HTGF.de or follow us on LinkedIn.   

    Media contact 
    High-Tech Gründerfonds Management GmbH 
    Tobias Jacob, Senior Marketing & Communications Manager  
    T.: +49 228 – 82300 – 121 
    t.jacob@htgf.de   

  • nuuEnergy Funding

    nuuEnergy Funding

    nuuEnergy Secures Multi-Million Euro Funding – and Aims to Rethink the Heat Pump Industry as a Premium Quality Provider 

    Heat pump installation and energy startup nuuEnergy has closed a seven-figure pre-seed funding round in spring 2025.

    Investors include HTGF, business angel club better ventures—with members such as energy entrepreneur Marco Vogt—alongside EnjoyVenture, Vireo Ventures, and Bynd. The funding will be used to launch and scale regional specialist craft businesses and to further digitalize the entire process from individual planning to installation and maintenance. 

    Unreliable installers, complex planning, opaque pricing—many Germans are still hesitant to switch to heat pumps. Digital providers often prioritize aggressive growth with a strong focus on sales, often at the expense of installation quality. Traditional craft businesses, on the other hand, frequently lack the capacity for in-depth consulting and planning. 

    This is where nuuEnergy comes in: Founded in 2023, the company combines the efficiency of digital processes with the quality and customer proximity of traditional craft businesses. 

    “Our customers want a local partner to guide them through the entire process – with top-notch quality in planning, installation, and service. That’s exactly what we offer through our regional businesses and digitalized planning,” says Tobias Klug, co-founder and CEO of nuuEnergy. 

    Photo: nuuEnergy

    The Better Way to Heat Pumps – Local, Digital, Human 

    nuuEnergy establishes its own regional craft businesses, fully integrated into the company. This allows nuuEnergy to merge the benefits of digital workflows – such as software-based planning and streamlined subsidy management—with the hands-on expertise and local presence of traditional tradespeople. A dedicated regional contact ensures smooth coordination and alignment throughout all stages. 

    “We’re the skilled trades’ answer to the big digital players who focus purely on sales and neglect quality,” says Julia Rafschneider, co-founder and CRO of nuuEnergy. “Our technicians are not just service providers – they’re the heart of our company. They are the experts, they plan, install, and deliver excellent craftsmanship. We provide the processes and technology to support them in doing just that.” 

    From initial consultation to final installation, all steps come from a single source. Tailored planning by skilled professionals ensures that every heat pump is precisely matched to its building. Proper sizing and high-quality installation reduce operating costs and extend the system’s lifespan. The Munich-based company has already successfully launched a second location in Hamburg, with a third site currently in planning. 

    A Growth Market with Enormous Potential 

    Demand for heat pumps is growing rapidly—despite a market dip in 2024. Following a record year in 2023, with over 350,000 installations in Germany (a 50% increase over 2022), the industry expects rising numbers again in 2025. By 2030, the German Heat Pump Association (BWP) forecasts up to 500,000 units installed annually to meet climate goals. The environmental impact is significant: switching to heat pumps can reduce a building’s CO₂ emissions by up to 70%. However, a shortage of skilled workers and inefficient processes are slowing progress. This is where nuuEnergy’s infrastructure comes in—to drive a new generation of the energy transition: locally rooted, digitally enabled, and human-centered. 

    For better ventures, this investment marks a key move in addressing one of the most critical levers in the energy transition. “Germany’s skilled trades sector holds the key to a successful heating transition—but a lack of skilled labor and inefficient processes are holding it back. nuuEnergy blends digitalization with excellent craftsmanship and offers a solution that doesn’t currently exist in the market—but is urgently needed,” says Tina Dreimann, founder and managing director of better ventures. 

    HTGF has been observing the heat pump market for some time and made a conscious decision to invest in the Munich-based startup: “Every house is different, and making renovations scalable is a challenge. We see nuuEnergy as the first convincing solution where a scalable model is emerging in close partnership with skilled trades—enabling millions of homes to switch to heat pumps without compromising quality,” says Johannes Weber, Principal at HTGF. 


    About nuuEnergy  
    Founded in 2023, nuuEnergy specializes in the planning and installation of heat pumps. With a unique business model, the company combines the advantages of digital processes with the quality and proximity of traditional craft businesses. The goal: to make the switch to climate-friendly heating as simple, efficient, and high-quality as possible. More at: www.nuuenergy.com 

    About better ventures  
    better ventures is Europe’s leading alliance for impact entrepreneurs. The network has invested in over 45 impact startups with more than 80 entrepreneurial angels and focuses on scalable business models that unite impact and returns. better ventures believes that entrepreneurs—founders, angels, and family business owners—are the most powerful lever to tackle the greatest challenges of our time. More at: www.betterventures.io 

    About EnjoyVenture 
    EnjoyVenture is one of Germany’s oldest venture capital firms, investing in early-stage technology and growth companies for over 25 years. More at: www.enjoyventure.vc  

    About Vireo Ventures 
    Vireo Ventures is a Berlin-based early-stage fund specializing in European startups in the energy and electrification sectors. More at: www.vireo.vc  

    About Bynd 
    Bynd is a leading Iberian startup fund that has been investing in disruptive European tech companies for 15 years. More at: www.bynd.vc  

    About HTGF – High-Tech Gründerfonds 
    HTGF is one of the leading and most active early-stage investors in Germany and Europe, financing start-ups in the fields of Deep Tech, Industrial Tech, Climate Tech, Digital Tech, Life Sciences and Chemistry. With its experienced investment team, HTGF supports start-ups in all phases of their development into international market leaders. HTGF invests in pre-seed and seed phases and can participate significantly in later-stage financing rounds. Across its funds, HTGF has over 2 billion euros under management. Since its inception in 2005, HTGF has financed more than 770 start-ups and achieved almost 200 successful exits.  

    Fund investors in the public-private partnership include the Federal Ministry for Economic Affairs and Energy, KfW Capital as well as 45 companies and family offices.  For more information, please visit HTGF.de or follow us on LinkedIn.   

    Media contact 
    High-Tech Gründerfonds Management GmbH 
    Tobias Jacob, Senior Marketing & Communications Manager  
    T.: +49 228 – 82300 – 121
    t.jacob@htgf.de   

  • Proxima Fusion raises €130M Series A to build world’s first stellarator-based fusion power plant in the 2030s 

    Proxima Fusion raises €130M Series A to build world’s first stellarator-based fusion power plant in the 2030s 

    Proxima Fusion raises €130M Series A to build world’s first stellarator-based fusion power plant in the 2030s 

    Europe’s fastest-growing fusion startup unlocks funding to advance commercial fusion technology and secure energy resilience for the continent. 

    Proxima Fusion, Europe’s fastest-growing fusion energy startup, today announced the close of a €130 million ($150 million) Series A funding round—marking it the largest private fusion investment round in Europe. 

    The Series A round was co-led by Cherry Ventures and Balderton Capital, with significant participation from UVC Partners, the DeepTech & Climate Fonds (DTCF), Plural, Leitmotif, Lightspeed, Bayern Kapital, HTGF, Club degli Investitori, OMNES Capital and Elaia Partners.  

    This brings Proxima Fusion’s total funding to more than €185 million ($200 million) in public and private capital, accelerating its mission to build the world’s first commercial fusion power plant based on a stellarator design.  

    Francesco Sciortino, CEO and Co-founder of Proxima Fusion, said: “Fusion has become a real, strategic opportunity to shift global energy dependence from natural resources to technological leadership. Proxima is perfectly positioned to harness that momentum by uniting a spectacular engineering and manufacturing team with world-leading research institutions, accelerating the path toward bringing the first European fusion power plant online in the next decade.” 

    Proxima Fusion Co-Founders (Photo: Proxima Fusion)

    Shifting global energy dependence  

    Proxima was founded in early 2023 as a spin-out from the Max Planck Institute for Plasma Physics (IPP), with which it continues to work closely together in a public-private partnership to lead Europe into a new era of clean energy. The EU, as well as national governments including Germany, the UK, France and Italy, are increasingly recognizing fusion as a strategic, generational technology essential for energy sovereignty, industrial competitiveness, and carbon-neutral economic growth.  

    By building on Europe’s long-standing public fusion investment and industrial supply chains, Proxima Fusion is laying the groundwork for a new high-tech energy industry—one that transforms the continent from a leader in fusion research to a global powerhouse in fusion deployment. 

    “We back founders solving humanity’s hardest problems — and few are bigger than clean, limitless energy,” said Filip Dames, Cherry Ventures Founding Partner. “Proxima Fusion combines Europe’s scientific edge with commercial ambition, turning world-class research into one of the most promising fusion ventures globally. This is deep tech at its best, and a bold signal that Europe can lead on the world stage.” 

    Proxima is taking a simulation-driven approach to engineering that leverages advanced computing and high-temperature superconducting (HTS) technology to build on the groundbreaking results of the IPP’s W7-X stellarator experiment. 

    Just earlier this year, together with the IPP, KIT and other partners, Proxima unveiled Stellaris. As the first commercial stellarator concept to integrate physics, engineering, and maintenance considerations from the outset, Stellaris has been widely recognized as a major breakthrough for the fusion industry, advancing the case for quasi-isodynamic (QI) stellarators as the most promising pathway to a commercial fusion power plant. 

    Daniel Waterhouse, Partner at Balderton Capital, said: “Stellarators aren’t just the most technologically viable approach to fusion energy—they’re the power plants of the future, capable of leading Europe into a new era of clean energy. Proxima has firmly secured its position as the leading European contender in the global race to commercial fusion. We are thrilled to partner with Proxima’s game-changing team of engineers, alongside Europe’s top manufacturers, to build a company that will be transformational for Europe.” 

    With this new funding, the company will complete its Stellarator Model Coil (SMC) in 2027, a major hardware demonstration that will de-risk HTS technology for stellarators and stimulate European HTS innovation. Proxima will also finalize a site for Alpha, its demo stellarator, for which it is in talks with several European governments already. Alpha is scheduled to begin operations in 2031, and will serve as the key step to demonstrate Q>1 (net energy gain) and move towards a first-of-a-kind fusion power plant . The company will continue to grow its 80+-strong team across its three offices: at the headquarters in Munich, at the Paul Scherrer Institute near Zurich (Switzerland), and at the Culham fusion campus near Oxford (UK). 

    “Fusion energy is entering a new era—moving from lab-based science to industrial-scale engineering,” said Dr. Francesco Sciortino. “This investment validates our approach and gives us the resources to deliver hardware that will be essential to make clean fusion power a reality.”  

    Ian Hogarth, Partner at Plural said: “Proxima Fusion exemplifies a new kind of European ambition – a full force effort to develop the world’s first fusion power plant. Since their first round of funding two years ago, Francesco and the team have hit extremely challenging milestones ahead of schedule and hired a team that spans plasma physics, advanced magnet design and simulation experts. Their peer-reviewed stellarator power plant design concept proves that fusion really can be commercially viable, and creates the opportunity for Europe to be first to the target.” 


    About Proxima Fusion 
    Proxima Fusion spun out of the Max Planck Institute for Plasma Physics (IPP) in 2023 to build the first generation of fusion power plants using QI-HTS stellarators. Proxima has since assembled a world-class team of engineers, scientists and operators from leading companies and institutions, such as the IPP, MIT, Harvard, SpaceX, Tesla, and McLaren. By taking a simulation-driven approach to engineering that leverages advanced computing and high-temperature superconductors to build on the groundbreaking results of the IPP’s W7-X stellarator, Proxima is leading Europe into a new era of clean energy, for good. 

    Media Contact: 
    Maria Dantz 
    Head of Communications 
    Proxima Fusion 
    Email: maria.dantz@gmail.com 
    Tel: +31 614715715 

    About HTGF – High-Tech Gründerfonds 
    HTGF is one of the leading and most active early-stage investors in Germany and Europe, financing start-ups in the fields of Deep Tech, Industrial Tech, Climate Tech, Digital Tech, Life Sciences and Chemistry. With its experienced investment team, HTGF supports start-ups in all phases of their development into international market leaders. HTGF invests in pre-seed and seed phases and can participate significantly in later-stage financing rounds. Across its funds, HTGF has over 2 billion euros under management. Since its inception in 2005, HTGF has financed more than 770 start-ups and achieved almost 200 successful exits.  
    Fund investors in the public-private partnership include the Federal Ministry for Economic Affairs and Energy, KfW Capital as well as 45 companies and family offices.  
    For more information, please visit HTGF.de or follow us on LinkedIn.   

    Media Contact 
    High-Tech Gründerfonds Management GmbH 
    Tobias Jacob, Senior Marketing & Communications Manager  
    T.: +49 228 – 82300 – 121
    t.jacob@htgf.de   

  • Mosanna Therapeutics Series A

    Mosanna Therapeutics Launches with $80 Million to Advance Novel Nighttime Nasal Spray for Obstructive Sleep Apnea 

    • Series A Funding to Advance MOS118 through Phase 2 Clinical Trials 
    • Biotech Veteran David Weber Appointed CEO to Drive Clinical Development 
    • Obstructive sleep apnea affects nearly 1 billion people globally, with the majority undiagnosed and underserved with current treatment options 

    Mosanna Therapeutics, a biotech company rethinking treatment of obstructive sleep apnea (OSA), today announced the close of $80 million in Series A funding. The company is developing an easy-to-use nighttime nasal spray to treat obstructive sleep apnea that will help restore the body’s natural airway control. The financing was led by Pivotal bioVenture Partners and EQT Life Sciences, along with Forbion, Broadview Ventures, and Norwest as co-lead investors. Returning investors included founding investor Forty51 Ventures as well as Supermoon Capital and High-Tech Gründerfonds (HTGF). 

    OSA is the most common sleep-related breathing disorder, affecting an estimated 1 billion people globally. Left untreated, OSA is linked to serious health risks including hypertension, cardiovascular disease, stroke, depression and excessive daytime sleepiness – contributing to workplace and car accidents. Despite OSA’s prevalence, treatment has largely focused on mechanical solutions that are often uncomfortable and disruptive. 

    Mosanna is pioneering a pharmaceutical solution for sleep apnea patients with MOS118, a nasal spray administered at bedtime that helps restore the body’s natural airway reflex. MOS118 targets the upper airway muscles that are responsible for maintaining airway patency. Research has shown that, for reasons yet unknown, the natural airway reflex in OSA patients exhibits decreased activity during sleep resulting in loss of airway patency and apnea. The new funding will support the advancement of MOS118 through Phase 2 development while also supporting expansion of Mosanna’s pipeline. 

    Mosanna also appointed veteran biotech leader David Weber, Ph.D., as President and Chief Executive Officer to guide Mosanna’s next stage of growth. With more than 30 years of experience spanning drug development, capital formation and corporate strategy, Dr. Weber has led teams across both public and private life sciences companies. Dr. Weber was also appointed to Mosanna’s Board of Directors. 

    “What sets Mosanna apart is its fundamentally different approach to sleep apnea, treating it as a neurological and muscular dysfunction rather than a purely mechanical issue,” said Daniela Begolo, Ph.D., Managing Director with EQT Life Sciences. “MOS118 is the first therapy with the potential to restore the body’s natural airway reflex with the simplicity of a nasal spray. MOS118 has the potential to dramatically improve adherence and outcomes in a patient population that has long been underserved.” 

    “With his deep expertise in biotech innovation and patient-centric therapies, Dr. Weber was the ideal choice to lead Mosanna into the next chapter,” said Jeni Lee, Ph.D., Partner with Pivotal bioVentures Partners. “We look forward to partnering with him and the Mosanna team to deliver on the promise of this life-changing sleep apnea treatment.” 

    “Mosanna is taking a truly transformational approach to sleep apnea treatment – offering a non-invasive, non-mechanical solution designed to seamlessly fit into daily life,” said Dr. Weber. “No one has sleep apnea while awake, because our bodies instinctively keep the airway open. Mosanna simply helps to restore this natural reflex during sleep – delivering a nasal spray alternative to invasive mechanical workarounds. With this funding, we’re accelerating development to bring this groundbreaking treatment to patients who desperately need better options.” 

    With this funding, Drs. Begolo and Lee joined the Board of Directors alongside Dmitrij Hristodorov, Ph.D., General Partner at Forbion; Hewmun Lau, M.B.A., Principal at Broadview Ventures; and Tiba Aynechi, Ph.D., General Partner at Norwest. They join existing board directors Sascha Oliver Bucher, M.B.A., CEFA, co-founder and Partner at Forty51 Ventures; and veteran biotech CEO Ben Machielse, who also serves as board chair.  


    About Mosanna Therapeutics  
    Mosanna Therapeutics is a clinical-stage biotech company pioneering a novel pharmaceutical approach to treating obstructive sleep apnea (OSA) with an easily administered nasal spray. Designed to help restore the body’s natural airway control during sleep, Mosanna’s lead therapy, MOS118, offers a drug-based alternative to traditional mechanical treatments and is currently being evaluated in a Phase 1 clinical trial. Founded in 2022, the company has raised more than $80 million from investors including Pivotal bioVenture Partners, EQT Life Sciences, Forbion, Norwest, Broadview Ventures, Forty51 Ventures, Supermoon Capital and High-Tech Gründerfonds (HTGF). Mosanna has offices in Redwood City, California and Basel, Switzerland. For more information, visit mosanna.com

    Media Contact 
    Jessica Flick 
    Cogenta Communications 
    jessica@cogentacom.com  

    About HTGF – High-Tech Gründerfonds 
    HTGF is one of the leading and most active early-stage investors in Germany and Europe, financing start-ups in the fields of Deep Tech, Industrial Tech, Climate Tech, Digital Tech, Life Sciences and Chemistry. With its experienced investment team, HTGF supports start-ups in all phases of their development into international market leaders. HTGF invests in pre-seed and seed phases and can participate significantly in later-stage financing rounds. Across its funds, HTGF has over 2 billion euros under management. Since its inception in 2005, HTGF has financed more than 770 start-ups and achieved almost 200 successful exits.  
    Fund investors in the public-private partnership include the Federal Ministry for Economic Affairs and Energy, KfW Capital as well as 45 companies and family offices.  
    For more information, please visit HTGF.de or follow us on LinkedIn.   

    Media contact 
    High-Tech Gründerfonds Management GmbH 
    Tobias Jacob, Senior Marketing & Communications Manager  
    T.: +49 228 – 82300 – 121
    t.jacob@htgf.de   

  • Medical Decision Alliance secures €3.3 million in seed funding

    Medical Decision Alliance secures €3.3 million in seed funding

    MDA – Medical Decision Alliance secures €3.3 million in seed funding to develop comprehensive surgical support systems 

    • Successful seed financing round led by High-Tech Gründerfonds (HTGF) with additional private investors and entrepreneurs  
    • Qualified MDA team systematically captures the experience and knowledge of the world’s leading surgeons and uses it to develop comprehensive and globally available assistance systems for the operating theatre.  
    • Already three partnerships with leading global medical technology companies to make surgical robots smarter. 

    Healthcare start-up MDA – Medical Decision Alliance has raised EUR 3.3 million in seed financing. The founding team, led by experienced life science entrepreneurs Dr Gunter Trojandt, Annett Christ and Daniel Bauer, has developed special software solutions that can be used to record the surgical techniques and decision-making routines of leading surgeons in detail and transfer them to AI-based assistance systems. 

    Making surgical robots smarter, pooling distributed knowledge. 

    Surgical robots and other specialised systems are increasingly being used in today’s surgery to improve the precision of procedures. However, individual decisions during surgery remain at the surgeon’s discretion and may be incorrect in some cases. Based on the decades of experience of renowned surgeons and in collaboration with leading manufacturers of robotic surgical systems, MDA is developing decision-making algorithms that suggest the most appropriate workflow for a wide range of patient situations.  

    In the future, surgical teams will be supported by intelligent algorithms as if the most experienced surgeon in the field were sitting right next to them. This will not only benefit the learning teams, but also the patients. 

    Making surgical knowledge available worldwide 

    A key priority is the education and training of the next generation of surgeons. MDA is committed to sharing expert knowledge through programmatic training solutions that are always up to date and available 24/7 – the digitalisation of surgical education. 

    “Together with MDA, we have digitised all key aspects of our surgical skills and developed an AI-based workflow engine called Virtual Proctor. Other clinics and doctors can now access it and benefit from our 20 years of experience – as far as I know there is no other system like it,” says Professor Markus Graefen, Medical Director of the Martini-Klinik at UKE GmbH, the Prostate Cancer Centre at the University Medical Centre Hamburg-Eppendorf. 

    MDA as a partner for innovative medical technology companies 

    In addition to robotics, which is the current focus of the MDA, the Virtual Proctor will also serve as a digital platform for interested MedTech partners to present their innovative products along specific indications. The focus will also be on the knowledge of experts who already use these products on a daily basis. This makes it easier for new customers to acquire additional expertise, as the Virtual Proctor provides conceptual knowledge, visual and clinically relevant content based on established standards and experience – real added value for clinics. 

    Dr Lena-Sophie Schütter, Investment Manager at HTGF, comments: “MDA’s well-coordinated team combines experience, expertise and a strong network – qualities that already characterised the success of their previous start-up. Through the structured development of a unique reference database, they are laying the foundation for AI-based training and decision-making algorithms. In this way, they are creating the conditions for greater safety, comparability and cross-clinic standards in robotic surgery – with the aim of providing better care for patients. ” 

    from left: Angela van Walsum-Koelewijn (Martini-Klinik), Daniel Bauer (MDA), Annett Christ (MDA), Dr. Gunter Trojandt (MDA), Prof. Dr. Alexander Haese (Martini-Klinik), Prof. Dr. Markus Graefen (Martini-Klinik) and Kathi Ehlert (Martini-Klinik) – Photo: MDA

    About MDA – Medical Decision Alliance 
    MDA was founded in 2023 by Dr Gunter Trojandt, Annett Christ and two business angels, Jozsef Bugovics and Nils Kröber. MDA has a total of 10 employees and is based in Leipzig, Germany. The founding team has been working together for more than 10 years and successfully sold their last joint company, SPI – Surgical Process Institute, to Johnson & Johnson – a leading global manufacturer of medical devices and surgical robots – in 2017. 

    The focus of SPI and MDA is on the operating room and improving the quality of patient outcomes. All developments are carried out in close collaboration with leading physicians, clinics and medical device companies.  

    With the capital from the current round of financing, MDA will double the size of its team, recruit additional clinics (knowledge providers) and medical device companies (collaborators), and develop AI-based surgical training and assistance solutions. 

    About HTGF – High-Tech Gründerfonds  
    HTGF is one of the leading and most active early-stage investors in Germany and Europe, financing startups in the fields of Deep Tech, Industrial Tech, Climate Tech, Digital Tech, Life Sciences and Chemistry. With its experienced investment team, HTGF supports startups in all phases of their development into international market leaders. HTGF invests in pre-seed and seed phases and can participate significantly in later-stage financing rounds. Across its funds, HTGF has over 2 billion euros under management. Since its inception in 2005, HTGF has financed more than 770 startups and achieved almost 200 successful exits.   

    Fund investors in the public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital as well as 45 companies and family offices.   For more information, please visit HTGF.de or follow us on LinkedIn.    
     
    Media contact  
    High-Tech Gründerfonds Management GmbH  
    Tobias Jacob, Senior Marketing & Communications Manager   
    T.: +49 228 – 82300 – 121  
    t.jacob@htgf.de    

  • Jupus Seed

    Jupus Seed

    JUPUS Completes Successful Seed Round of €6.5 Million – Acton Capital as Lead Investor

    The Cologne-based Legal Tech startup JUPUS has raised €6.5 million in funding. The seed round was led by Acton Capital and existing investors such as HTGF (High-Tech Gründerfonds) and business angels.

    With this fresh capital, JUPUS plans to further develop its product, expand its market share, and shape the future of legal work. Already, hundreds of law firms are using JUPUS’s AI software to automate tasks through Artificial Intelligence.

    Team of JUPUS (Photo: JUPUS)

    AI Takes Over the Lawyer’s Daily Routine
    JUPUS offers the first fully automated AI solution for law firms that not only automates administrative tasks but also communicates directly with clients. JUPUS’s AI secretary is unique in the market: It enables law firms to manage their processes from the first call to the final legal document entirely through AI. Standard processes are not only digitized but fully automated. Hundreds of law firms in Germany are already successfully using the solution in their daily work. JUPUS addresses the industry’s most pressing challenge: the growing shortage of skilled workers.

    The Answer to the Industry’s Biggest Problem The increasing shortage of legal assistants is pushing law firms to their limits. Delayed response times, dissatisfied clients, and overwhelmed teams are the consequences. JUPUS addresses this issue by having AI take over time-consuming tasks, ignificantly relieving the law firm staff.

    Currently, law firms using JUPUS save an average of 40 work hours per month, and by 2026, this number is expected to increase to over 100 hours per month thanks to new AI functionalities. This allows law firms to better utilize their limited resources, increase client satisfaction, and remain operational despite the shortage of skilled workers. Tasks that once took hours are now completed in seconds with JUPUS, making efficiency the new standard in law firm operations.

    “We are at the beginning of a new era for the legal market,” says René Fergen, founder and CEO of JUPUS. “Artificial Intelligence will fundamentally change how legal work is organized and executed – with entirely new opportunities for law firms. With JUPUS, we are leading this transformation and enabling law firms to radically simplify and accelerate their workflows. Our goal is to mitigate the growing shortage of skilled workers and give law teams the freedom to focus again on what really matters: advising their clients.”

    JUPUS Automates What Law Firms Used to Need Entire Teams For
    Unlike previous solutions, JUPUS covers the entire process of law firm work – from the first client contact to the final legal document. The AI software communicates directly with clients, handles administrative tasks, coordinates appointments, and creates required documents. JUPUS is the first legal AI solution to fully integrate client communication, mandate preparation, and document drafting in one platform, fundamentally redefining law firm operations.

    New Funding to Expand the AI Solution in Law Firms Since its founding in 2022, the team, led by founders René Fergen and Jannis Gebauer, has already supported hundreds of law firms in Germany, helping them process their client requests with JUPUS. With this new funding, the company will continue developing its AI software and expand its market share.

    Acton Capital, one of Europe’s leading investors in digital business models, is confident in the vision and potential of JUPUS: “The legal market is undergoing a transformation, and JUPUS is ideally positioned to lead this change. The team has impressively shown how legal processes can be automated using AI – resulting in massive efficiency gains for law firms. We see JUPUS as having the potential to set a new standard in the legal world. We look forward to supporting the team on this journey,” explains Fritz Oidtmann, Managing Partner at Acton Capital.

    In addition to JUPUS, Acton Capital has supported well-known companies such as the leading e-commerce platform Etsy and the Canadian legal tech company Clio. JUPUS had previously raised €1.3 million in a pre-seed round from the High-Tech Gründerfonds and business angels such as Micha Grüber (Co-Founder 1KOMMA5) and Kilian Kaminski (Co-Founder Refurbed). With the current round of €6.5 million, this amount has now been quintupled, marking a significant step in the company’s expansion.

    About JUPUS
    JUPUS develops the first AI secretary specifically for law firms, enabling law teams to comprehensively automate their workflows. From the first call to the final legal document, JUPUS supports all central process steps fully through AI. Already, hundreds of law firms rely on JUPUS’s AI secretary.

    About Acton Capital
    Acton Capital is an international venture capital firm with offices in Munich and Vancouver. Since 1999, the team has been investing in technology-based business models from Europe and North America. With over two decades of experience and a deep understanding of digital transformation, Acton Capital has supported more than 100 startups, including global leaders such as Alphasights, Clio, HomeToGo, and Mambu. For more information, visit www.actoncapital.com.

    About HTGF – High-Tech Gründerfonds 
    HTGF is one of the leading and most active early-stage investors in Germany and Europe, financing start-ups in the fields of Deep Tech, Industrial Tech, Climate Tech, Digital Tech, Life Sciences and Chemistry. With its experienced investment team, HTGF supports start-ups in all phases of their development into international market leaders. HTGF invests in pre-seed and seed phases and can participate significantly in later-stage financing rounds. Across its funds, HTGF has over 2 billion euros under management. Since its inception in 2005, HTGF has financed more than 770 start-ups and achieved almost 200 successful exits.  
    Fund investors in the public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital as well as 45 companies and family offices.  
    For more information, please visit HTGF.de or follow us on LinkedIn.   

    Media contact 
    High-Tech Gründerfonds Management GmbH 
    Tobias Jacob, Senior Marketing & Communications Manager  
    T.: +49 228 – 82300 – 121
    t.jacob@htgf.de   

  • HTGF backs Emerge Tech

    HTGF backs Emerge Tech

    HTGF backs Emerge Tech: AI Agents empower SMEs facing skilled worker shortage

    • HTGF invests in Emerge Tech, which uses AI agents to make employers more visible, improve the quality of applicants and reduce recruitment costs significantly.
    • Proof of impact: 40% better applicant matching, 87% cheaper than agencies and 54% less HR effort.
    • Seed round in preparation: Emerge is developing the leading AI platform for employer branding and people experience in medium-sized businesses.
    • Signal-sending founding team: combining tech innovation, HR vision and growth expertise, a Babbel co-founder, the founder of DEBA and an international scale-up architect are set to achieve new heights.

    High-Tech Gründerfonds (HTGF) and the Heimatboost investment community are investing in Emerge Tech GmbH, a Berlin-based HR tech start-up that uses AI-powered employer branding to put SMEs on an equal footing with large corporations by making the process more accessible, automated and effective. The investment will fund the development of the platform and prepare the seed round.

    “To solve the skills shortage, we must start with employers. Our AI agents will create game-changing opportunities, finally enabling smaller teams to stand out as employers and reshape HR.”

    Daniel Braun, Co-Founder & CEO, Emerge

    AI against the skills shortage: highly efficient and genuinely authentic.

    Although the shortage is not expected to peak until 2035, companies are already struggling to establish a presence in the labour market. Rather than relying on agencies, Emerge uses AI: Creative Carla defines your identity and message, while Channel Charly delivers them to the right channels based on data — precisely, measurably and scalably. What was once only available to large corporations with big budgets is now accessible to medium-sized companies too, with measurable success: a 40% better fit between people and organisation, 87% lower costs compared to agencies and 54% less effort in everyday recruitment. Thanks to AI, employer branding is no longer a one-off campaign, but an ongoing dialogue between companies and potential employees.

    “Employer branding has long been a privilege reserved for big brands. However, talent doesn’t make decisions based on budget; authenticity wins. That’s exactly where our AI comes in.”

    Reiner Kriegler, Co-Founder & CPO, Emerge

    Strategy & Outlook

    Until the end of 2025, Emerge’s focus will be on improving product quality and increasing user numbers with Carla and Charly, with the aim of creating a scalable, robust AI agent model. A seed round is planned for late 2025, after which the focus will shift towards internationalisation. At the same time, a new line of agents is being developed to support the entire people experience, from onboarding to performance management.

    “The complementary and experienced founding team at Emerge immediately impressed us. Their blend of HR expertise and technological know-how is precisely what is required to facilitate the long-term digital transformation of medium-sized businesses. We are delighted to support Emerge on this journey as an investor.”

    Christian Arndt, Principal at HTGF

    Founding team

    • Daniel Braun scaled the HR tech start-up WorkGenius to £150 million in revenue in the US and is now CEO of Emerge.
    • Wolf Reiner Kriegler: Employer branding pioneer and founder of the German Employer Branding Academy. Now CPO of Emerge.
    • Thomas Holl is the co-founder of the language learning app Babbel and is now the CTO of Emerge.

    With Emerge Tech, they are bringing technology to employers in need of real change.

    Founding team of Emerge Tech (Photo: Emerge Tech)


    About Emerge Tech

    Founded in Berlin in 2024, Emerge Tech GmbH develops specialised AI agents that digitise and enhance the employer attractiveness of small and medium-sized businesses faster, more efficiently and more affordably than any agency service. In 2025, the focus will be on user growth and product maturity, followed by international expansion in 2026 with new agents covering the entire people experience. Find out more about AI agents at emerge-tech.io.

    Media contact
    Emerge Tech GmbH
    Reiner Kriegler
    Co-Founder & CPO
    E-Mail: reiner@emerge-tech.io

    About HTGF – High-Tech Gründerfonds
    HTGF is one of the leading and most active early-stage investors in Germany and Europe, financing startups in the fields of Deep Tech, Industrial Tech, Climate Tech, Digital Tech, Life Sciences and Chemistry. With its experienced investment team, HTGF supports startups in all phases of their development into international market leaders. HTGF invests in pre-seed and seed phases and can participate significantly in later-stage financing rounds. Across its funds, HTGF has over 2 billion euros under management. Since its inception in 2005, HTGF has financed more than 770 startups and achieved almost 200 successful exits.  
    Fund investors in the public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital as well as 45 companies and family offices.  
    For more information, please visit HTGF.de or follow us on LinkedIn.   

    Media contact
    High-Tech Gründerfonds Management GmbH
    Tobias Jacob, Senior Marketing & Communications Manager
    T.: +49 228 – 82300 – 121
    t.jacob@htgf.de  

  • desk.ly secures seven-figure funding for the future of hybrid workplaces

    desk.ly secures seven-figure funding for the future of hybrid workplaces

    desk.ly secures seven-figure funding for the future of hybrid workplaces

    Osnabrück-based start-up desk.ly, provider of an AI-powered platform for modern workplace management, announces the successful closing of a seven-figure financing round from HTGF for its next growth phase. With the new capital, desk.ly will expand its AI capabilities, improve data analysis and strengthen its market position through strategic partnerships in the furniture, construction and workplace consulting sectors.

    Strong demand for intelligent workplace solutions

    desk.ly addresses the growing challenges of hybrid working models with features such as desk sharing, smart booking suggestions and data-driven office management. Based on past bookings, teammates’ workspace choices and individual needs and preferences, desk.ly suggests the optimal workspace.

    Hybrid working models offer companies new opportunities for efficient office use

    With desk.ly’s desk sharing software, you can reduce vacancies, optimise resources and make office space more flexible – whether through more compact space planning or subletting. More efficiency, less unused space.

    Since its founding in 2021, desk.ly has been helping companies transition to hybrid working models. With over 1,000 customers, including Eurowings, Funke Medien Gruppe, OMR, Volksbank and Fraunhofer, and more than 100,000 active users, desk.ly is one of the leading platforms for intelligent workplace management in Europe. The team now consists of around 40 employees.

    Felix Mohr, CEO and founder of desk.ly, says: “In the new world of work, efficiency, flexibility and data intelligence are the keys to success. That’s why we’re building desk.ly – together with our customers and based on our belief that every workplace should be smart, sustainable and people-centric.”

    More efficiency, less cost

    Desk sharing software helps companies reduce their energy costs, optimise their building structure and tailor services to their needs. Flexible space planning and optimised space utilisation create a more efficient office infrastructure that not only improves resource utilisation, but also reduces operating costs in the long term – a clear gain in efficiency and a quick return on investment (ROI).

    Optimise space and reduce costs

    Hybrid working models and shared desks mean that offices are on average 40% less occupied. This unused space offers huge savings potential – from reduced rental and energy costs to lower cleaning and catering expenses. desk.ly helps companies turn this potential into concrete financial benefits and sustainably reduce their operating costs.

    In addition to reducing rental costs, desk.ly can also optimise ancillary costs such as energy, cleaning and food – benefiting the company’s bottom line and contributing to sustainability.

    Next steps: AI features and scaling

    desk.ly will use the funding to further develop its AI-based features, such as personalised booking recommendations and intelligent agents. desk.ly will also focus on strategic partnerships with leading brands in the furniture, construction and workplace consultancy industries to create a holistic solution for its customers.

    desk.ly has achieved strong growth with impressive capital efficiency and has successfully positioned itself in a dynamic market. We are excited to accompany the strong team on its journey and believe that desk.ly will play a key role in shaping the future of work environments,’ said Maurice Kügler, Senior Investment Manager at HTGF

    Founders of desk.ly (Photo: desk.ly)

    About desk.ly
    desk.ly is the AI-powered workplace management platform that organises hybrid work environments in an efficient, sustainable and user-centric way – from desk sharing and smart booking recommendations to data-driven office management. For over two years, desk.ly has been the category leader in workplace management and desk booking on platforms such as OMR Reviews. Further information: www.desk.ly

    About HTGF – High-Tech Gründerfonds 
    HTGF is one of the leading and most active early-stage investors in Germany and Europe, financing startups in the fields of Deep Tech, Industrial Tech, Climate Tech, Digital Tech, Life Sciences and Chemistry. With its experienced investment team, HTGF supports startups in all phases of their development into international market leaders. HTGF invests in pre-seed and seed phases and can participate significantly in later-stage financing rounds. Across its funds, HTGF has over 2 billion euros under management. Since its inception in 2005, HTGF has financed more than 770 startups and achieved almost 200 successful exits.
    Fund investors in the public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital as well as 45 companies and family offices.  
    For more information, please visit HTGF.de or follow us on LinkedIn.   

    Media contact 
    Tobias Jacob, Senior Marketing & Communications Manager  
    T.: +49 228 – 82300 – 121 
    t.jacob@htgf.de

  • 7Learnings Secures €10M+ Series B

    7Learnings Secures €10M+ Series B

    7Learnings Secures €10M+ Series B to Accelerate Global Expansion of Its Retail AI Platform

    • 7Learnings secured €10 million in Series B funding to advance its predictive pricing and retail optimization technology, and to scale in North America and beyond.
    • The round was led by Acton Capital, renowned for its investments in companies such as Etsy, mytheresa, Clio, and SoSafe, with the continued backing from High-Tech Gründerfonds (HTGF).
    • The funding comes amidst renewed supply chain uncertainties due to the impact of US tariffs, highlighting the value of 7Learnings’ predictive pricing and retail optimization solutions in driving measurable business outcomes.

    7Learnings, the leading provider of AI-powered retail optimization technology, today announced the successful close of its Series B funding round, securing over €10 million in new investment. The funding round was led by Acton Capital, one of Europe’s leading venture capital funds with a focus on technology start-ups. The existing investor High-Tech Gründerfonds also participated in the round, renewing their commitment. The funding will accelerate 7Learnings’ international expansion, with a strategic focus on entering the North American market.

    Unlike many high-growth tech startups, 7Learnings has reached profitability ahead of its Series B round, underscoring the strength and scalability of its business model. This new investment is earmarked entirely for growth, allowing the company to capitalize on its momentum and rapidly extend its global footprint.

    “We’ve built a profitable business by delivering measurable results for our customers,” said Felix Hoffmann, CEO and Co-Founder of 7Learnings. “Amidst trade uncertainties, persistent inflation, and global supply chain challenges, better decision intelligence has become business-critical for brands and e-commerce merchants. This investment allows us to bring our technology to even more retailers worldwide, with North America as our next major focus.”

    7Learnings has emerged as a clear market leader in AI-driven pricing, trusted by leading global retailers and validated through hundreds of A/B tests. The company’s Retail AI platform goes beyond dynamic pricing, offering predictive capabilities that align marketing campaigns with pricing strategies and optimize product orders, unlocking full-margin potential across the value chain.

    “With the continued pressure from inflation and shifting consumer behavior, as well as the renewed impact of U.S. tariffs on our sourcing and pricing strategy, 7Learnings has been instrumental in helping us navigate these challenges. Its AI-powered pricing and retail optimization tools allow us to adapt quickly, make smarter pricing decisions, and protect our margins without compromising on brand integrity or customer experience,” says Timo Bethlehem, Managing Director at meinemarkenmode.de. The fashion retailer has been working with 7Learnings for 5 years, achieving a 13% revenue increase by leveraging predictive pricing.

    With its unique ability to synchronize pricing, marketing, and ordering decisions through machine learning, 7Learnings empowers retailers to make smarter, faster, and more profitable decisions at scale.

    “Pricing is one of the most powerful levers for driving profitability in e-commerce. What impressed us about 7Learnings is their state-of-the-art proprietary AI technology, which consistently outperforms the competition. They’ve already established themselves as the market leader in Germany, and we’re excited to support their international expansion,” says Sebastian Wossagk, managing partner at Acton Capital.

    “At a time when AI has seemingly infused any technology-driven business, it is more important than ever to look at its ROI. The AI applications provided by 7Learnings deliver a clear and tangible effect on their customers’ bottom line. We have been impressed with the leadership’s vision and drive, and are happy to double down on our investment,” adds Martin Möllmann, Principal at HTGF.

    Founders of 7learnings: Eiko van Hettinga, Felix Hoffmann, and Martin Nowak (Photo: 7learnings)

    About 7Learnings
    7Learnings provides an AI-powered retail optimization platform for B2C companies, pioneering the overarching optimization of pricing, performance marketing, and product ordering. With 7Learnings’ machine learning algorithm, retailers and brands can predict the impact of pricing decisions, determine the optimal price for all products, and reduce manual labor by up to 80 percent. The solution has been rigorously tested in numerous A/B experiments and consistently delivers measurable performance improvements and profit increases of more than ten percent.

    7Learnings was founded in Berlin in 2019 by Felix Hoffmann, Eiko van Hettinga, and Martin Nowak. Its clients include international companies such as Westwing, Bonprix, Tom Tailor, Tamaris, and DK Company

    About HTGF – High-Tech Gründerfonds  
    HTGF is one of the leading and most active early-stage investors in Germany and Europe, financing startups in the fields of Deep Tech, Industrial Tech, Climate Tech, Digital Tech, Life Sciences and Chemistry. With its experienced investment team, HTGF supports startups in all phases of their development into international market leaders. HTGF invests in pre-seed and seed phases and can participate significantly in later-stage financing rounds. Across its funds, HTGF has over 2 billion euros under management. Since its inception in 2005, HTGF has financed more than 770 startups and achieved almost 200 successful exits.   

    Fund investors in the public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital as well as 45 companies and family offices.   For more information, please visit HTGF.de or follow us on LinkedIn.    
     
    Media contact  
    High-Tech Gründerfonds Management GmbH  
    Tobias Jacob, Senior Marketing & Communications Manager   
    T.: +49 228 – 82300 – 121  
    t.jacob@htgf.de    

  • Eyeo raises €15 million seed round to give cameras perfect eyesight

    Eyeo raises €15 million seed round to give cameras perfect eyesight

    Eyeo raises €15 million seed round to give cameras perfect eyesight

    Breakthrough color-splitting photonics innovation triples light sensitivity and breaks sensor resolution limits for a new era in ultra-compact, high-performance imaging

    • Light carries everything in an image – and yet, all 10 billion image sensors sold yearly are 70% blind because of decades-old color filtering technology.
    • Eyeo replaces traditional filters with advanced color-splitting technology originating from imec, world-leading research and innovation hub in nanoelectronics and digital technologies. For the first time, photons are not filtered but guided to single pixels, delivering maximum light sensitivity and unprecedented native color fidelity, even in challenging lighting conditions.
    • Compatible with any sensor, eyeo’s single photon guiding technology breaks resolution limits – enabling truly effective sub-0.5-micron pixels for ultra-compact, high-resolution imaging in XR, industrial, security, and mobile applications – where image quality is the top purchasing driver.

    eyeo today announced it has raised €15 million in seed funding, co-led by imec.xpand, Invest-NL, joined by QBIC fund, High-Tech Gründerfonds (HTGF) and Brabant Development Agency (BOM). Eyeo revolutionizes the imaging market for consumer, industrial, XR and security applications by drastically increasing the light sensitivity of image sensors. This breakthrough unlocks picture quality, color accuracy, resolution, and cost efficiency, which was never before possible in smartphones and beyond.

    The €15 million raised will drive evaluation kit development, prepare for scale manufacturing of a first sensor product, and expand commercial partnerships to bring this breakthrough imaging technology to market.

    The Problem: Decades-old color filter technology throws away 70% of light, crippling sensor performance

    For decades, image sensors have relied on the application of red, green, and blue color filters on pixels to make your everyday color picture or video.  Color filters, however, block a large portion of the incoming light, and thereby limit the sensitivity of the camera. Furthermore, they limit the scaling of the pixel size below ~0.5 micron. These longstanding issues have stalled advancements in camera technology, constraining both image quality and sensor efficiency. In smartphone cameras, manufacturers have compensated for this limitation by increasing the sensor -and thus camera- size, to capture more light. While this improves low-light performance, it also leads to larger, bulkier cameras. Compact, high-sensitivity image sensors are essential for slimmer smartphones and emerging applications such as robotics and AR/VR devices, where size, power efficiency, and image quality are crucial.

    The Breakthrough: Color-splitting via vertical waveguides

    Eyeo introduces a novel image sensor architecture that eliminates the need for traditional color filters, making it possible to maximize sensitivity without increasing sensor size. Leveraging breakthrough vertical waveguide-based technology that splits light into colors, eyeo develops sensors that efficiently capture and utilize all incoming light, tripling sensitivity compared to existing technologies. This is particularly valuable in low-light environments, where current sensors struggle to gather enough light for clear, reliable imaging. Additionally, unlike traditional filters that block certain colors (information that is then interpolated through software processing), eyeo’s waveguide technology allows pixels to receive complete color data. This approach instantly doubles resolution, delivering sharper, more detailed images for applications that demand precision, such as computational photography, machine vision, and spatial computing.

    Jeroen Hoet, CEO of eyeo: “Eyeo is fundamentally redefining image sensing by eliminating decades-old limitations. Capturing all incoming light and drastically improving resolution is just the start—this technology paves the way for entirely new applications in imaging, from ultra-compact sensors to enhanced low-light performance, ultra-high resolution, and maximum image quality. We’re not just improving existing systems; we’re creating a new standard for the future of imaging.”

    Market Readiness and Roadmap

    Eyeo has already established partnerships with leading image sensor manufacturers and foundries to ensure the successful commercialization of its technology. The €15M seed funding will be used to improve its current camera sensor designs further, optimizing the waveguide technology for production scalability and accelerating the development of prototypes for evaluation. By working closely with industry leaders, eyeo aims to bring its advanced camera sensors to a wide range of applications, from smartphones and VR glasses to any compact device that uses color cameras. The first evaluation kits are expected to be available for selected customers within the next two years. Eyeo is headquartered in Eindhoven (NL), with an R&D office in Leuven (BE).

    Anne Umbach, Investment Manager at HTGF, says: “Eyeo’s cutting-edge technology, which allows for more precise color detection and outstanding image quality even in low-light conditions, positions the company as a potential European tech champion. With a highly innovative technology and a strong, complementary and experienced team, Eyeo is well-equipped to establish a global presence in the expanding surveillance and security market, as well as in the smartphone industry.”

    Eyeo’s founding team combines extensive industry knowledge with imec’s cutting-edge expertise: Jan Genoe (scientific fellow and co-founder), Jeroen Hoet (CEO and co-founder), Gerd Van den Branden (CPO and co-founder), Alden Carracillo (COO and co-founder) – Photo: eyeo
    3D rendering of eyeo’s waveguide structure

    About eyeo
    Eyeo is redefining imaging with the world’s most advanced nanophotonic color-splitting technology. For the first time, image sensors can capture all of incoming light, overcoming the current 30% limit imposed by decades-old color filter technology. Instead of filtering photons, Eyeo’s breakthrough technology guides them directly to individual pixels, unlocking full light sensitivity and native color fidelity, even in the most challenging conditions. Compatible with any CMOS sensor platform, Eyeo’s single-photon guiding capability also breaks resolution barriers, enabling sub-0.5-micron pixels for ultra-compact, high-performance imaging in XR, industrial, security, and mobile applications where image quality is critical.

    Learn more at www.eyeo-imaging.com

    This operation benefits from the support from the European Union under the InvestEU Fund

    Press Contact

    PR-Agentur: Mike Sottak // +1 650 248-9597 // mike@wiredislandpr.com 

    Eyeo: press@eyeo-imaging.com

    About HTGF – High-Tech Gründerfonds 
    HTGF is one of the leading and most active early-stage investors in Germany and Europe, financing start-ups in the fields of Deep Tech, Industrial Tech, Climate Tech, Digital Tech, Life Sciences and Chemistry. With its experienced investment team, HTGF supports start-ups in all phases of their development into international market leaders. HTGF invests in pre-seed and seed phases and can participate significantly in later-stage financing rounds. Across its funds, HTGF has over 2 billion euros under management. Since its inception in 2005, HTGF has financed more than 770 start-ups and achieved almost 200 successful exits.  
    Fund investors in the public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital as well as 45 companies and family offices.  
    For more information, please visit HTGF.de or follow us on LinkedIn.   

    Media contact 
    High-Tech Gründerfonds Management GmbH 
    Tobias Jacob, Senior Marketing & Communications Manager  
    T.: +49 228 – 82300 – 121
    t.jacob@htgf.de   

  • eeden – completion of Series A funding

    eeden – completion of Series A funding

    eeden Closes €18M Series A Financing to Scale its Breakthrough Textile Recycling Technology

    German tech startup eeden, which has developed a groundbreaking textile recycling technology, announces the completion of its €18 million Series A funding round.

    The round was led by Forbion, a leading venture capital firm based in The Netherlands, through its BioEconomy Fund. Also joining as new investors are Henkel Ventures, the strategic venture capital fund of Henkel, with deep expertise in surface and coating technologies through its consumer and industrial business, and NRW.Venture, the Venture Fund of NRW.BANK, North Rhine-Westphalia´s development bank. All existing investors reinvested in the round, including the venture capital investors TechVision Fund (TVF), High-Tech Gründerfonds (HTGF) and D11Z. Ventures – the early-stage nvestment arm of the family office of Dieter Schwarz. The funding will enable eeden to build its demonstration plant in Münster, optimize large-scale processing, and establish commercial projects with key players in the textile industry.

    A major step toward circularity

    Ongoing challenges including rising costs, scarcity of resources, material volatility, and growing regulatory hurdles continue to strain the textile industry. To remain competitive, brands and manufacturers are increasingly looking for textile materials that combine high performance, scalability, and circularity at price parity. eeden addresses this need with its breakthrough in chemical recycling technology that recovers pure cellulose and PET building blocks (monomers) from cotton-polyester blends. Their products can be used to produce virgin-quality lyocell, viscose, and polyester fibers thereby offering a resource-efficient alternative to conventional fibers and unlocking new circular value chains.

    Steffen Gerlach, CEO & Co-Founder of eeden: “Over the past few years, we have developed a proven solution that has the potential to meet the industry’s long-term need for cost-efficient and high-performing circular materials. We are proud that our new and existing investors believe in our approach and share our vision. With their support, we are ready to scale our technology and turn textile waste into materials the industry truly needs.”

    With increasing textile waste comes increased regulation. As of January 2025, EU member states are required to implement separate collection systems for used textiles. eeden’s technology provides a pragmatic solution that is capable of processing complex blended materials.

    Alex Hoffmann, General Partner at Forbion noted, “eeden has developed a pioneering solution that can make large-scale textile recycling not only technologically feasible, but also commercially viable in the near future. We see tremendous potential in their approach and are excited to support the team as they bring this breakthrough technology to industrial scale.”

    Björn Lang, Partner TVF, “As an early investor, it’s great to see how the team has turned a vision into a validated process and strong strategic partnerships. The progress they’ve made shows what’s possible when the right people and strong science meet real customer needs. We’re excited to keep backing the team as they scale their impact.”

    Nik Raupp, Principal at HTGF: “The founders of Eeden have consistently achieved impressive results over the past three years. They have exceeded their ambitious targets and gained new strategic partners. My expectations have been more than fulfilled, and I am therefore looking forward with great anticipation to our future collaboration and the promising developments of the years to come.”

    The new eeden demonstration facility in Münster, Germany follows the successful technology validation of its pilot plant with industrial partners. This €18 million Series A financing will enable the company to optimize large-scale processing and establish commercial projects with key players in the textile industry.

    l. Steffen Gerlach, CEO & Co-Founder – r. Dr. Tobias Börnhost, CTO & Co-Founder (photo: eeden)

    About eeden
    eeden is a tech company based in Münster, Germany, pioneering the chemical recycling of cotton-polyester textiles. Founded in 2019, eeden has developed a breakthrough technology that efficiently separates and recovers cellulose and PET monomers, which fiber producers transform into virgin-quality lyocell, viscose, and polyester fibers – enabling the transition toward a fully circular textile industry. Find out more at eeden.world

    About Forbion
    Forbion is a leading global venture capital firm with deep expertise in Europe and offices in Naarden, The Netherlands, Munich, Germany and Boston, USA. Forbion invests in innovative biotech companies, managing approximately €5 billion across multiple fund strategies that cover all stages of (bio-) pharmaceutical drug development. In addition, Forbion leverages its biotech expertise beyond human health to address ‘planetary health’ challenges through its BioEconomy fund strategy, which invests in companies developing sustainable solutions in food, agriculture, materials, and environmental technologies. Forbion’s team consists of over 30 investment professionals that have built an impressive performance track record since the late nineties with 128 investments across 11 funds. Forbion’s record of sourcing, building and guiding life sciences companies has resulted in many approved breakthrough therapies and valuable exits. Forbion typically selects impactful investments that will positively affect the health and well-being of people and the planet, as well as meet its financial return objectives. The firm is a signatory to the United Nations Principles for Responsible Investment. Forbion operates a joint venture with BGV, the manager of seed and early-stage funds, especially focused on Benelux and Germany.

    About Henkel Ventures
    Henkel Ventures is the corporate venture capital arm of Henkel, following a balanced approach with strategic fit and solid financial return. The venture unit partners with start-ups for co-innovation and invests in early-stage, late seed until B rounds in the areas of Consumer Packaged Goods (CPG), Adhesive Technologies, Sustainability and Digital Commerce. Find out more at Henkel Ventures

    About NRW.Venture
    NRW.Venture is the venture capital fund of NRW.BANK. In this way, the promotional bank for North RhineWestphalia responds to the scarce supply of financing for young, innovative and often technology-oriented companies, which often do not have sufficient access to loans. Their main asset is a new market idea – which is why their chances of success are often difficult to assess. Together with private-sector investors, NRW.Venture invests up to 15 million euros of equity in such start-ups over several financing rounds – typically from the second round onwards – with NRW.BANK taking a minority stake with a term of three to seven years. But the Bank not only provides capital – an experienced team is the key to joint success. NRW.Venture’s investment professionals have many years of venture capital experience, often complemented by technology and start-up experience, and use their expertise and network to ensure that start-ups have the best chances of success.

    About TVF
    TechVision Fund (TVF) is a leading early-stage VC fund from Aachen, Germany – with a focus on technology start-ups in the pre-seed to Series A phases. TVF focuses on outstanding teams from the Rhineland region, including the neighbouring Netherlands and Belgium. The TVF management has experience from four fund generations and currently has over € 100 million in assets under management. The funds are backed by strong investors such as NRW.BANK, eight savings banks (Sparkassen) from western NRW and more than 15 successful entrepreneurs.
    The TVF supports start-up teams with proximity, network and expertise and paves the way for them to become the next international industry leader. Through the S-UBG Group network, the TVF offers unique access to over 150 successful companies in various industries and establishes contacts between start-ups and their first customers, partners and consultants.
    TVF – Brain | Cash | Proximity
    Find out more at www.tvf.vc

    About D11Z. Ventures
    D11Z. Ventures is a dynamic early-stage investor specializing in digital and AI startups across Germany and Europe. As a single-family-office VC, D11Z. Ventures pursues the vision of shaping the digital future as a leading European investor in AI, IoT, and SaaS. With deep experience, expertise, and agility, D11Z. Ventures drives digital transformation and maintains strong ties to tech-focused SMEs and global market leaders. At its core, the D11Z. Ventures seeks out founders with visionary ideas to sustainably shape the digital future. True to its motto “Shaping Tomorrow, Today,” D11Z. Ventures brings visionary ideas to life today.
    Learn more at https://d11z.com/

    About HTGF – High-Tech Gründerfonds  
    HTGF is one of the leading and most active early-stage investors in Germany and Europe, financing start-ups in the fields of Deep Tech, Industrial Tech, Climate Tech, Digital Tech, Life Sciences and Chemistry. With its experienced investment team, HTGF supports start-ups in all phases of their development into international market leaders. HTGF invests in pre-seed and seed phases and can participate significantly in later-stage financing rounds. Across its funds, HTGF has over 2 billion euros under management. Since its inception in 2005, HTGF has financed more than 770 start-ups and achieved almost 200 successful exits.   
    Fund investors in the public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital as well as 45 companies and family offices.   
    For more information, please visit HTGF.de or follow us on LinkedIn.    

    Media contact  
    High-Tech Gründerfonds Management GmbH  
    Tobias Jacob, Senior Marketing & Communications Manager   
    T.: +49 228 – 82300 – 121 
    t.jacob@htgf.de    

  • DXI takes customer interaction to a new level

    DXI takes customer interaction to a new level

    DXI takes customer interaction to a new level: Pre-seed financing secures AI leadership in the field of “digital customer twins” 

    • DXI GmbH secures significant pre-seed financing from HTGF and business angels to scale its PersonaX® AI platform.  
    • The platform enables realistic, interactive “digital customer twins” based on LIA technology and >70% cost savings in market research. 
    • With PersonaX®, companies can act proactively, realistically, and in real time from the customer’s perspective – a milestone for customer experience and insights.  
    • “Our vision is a realistic dialogue with every digital B2B or B2C customer twin,” say founders Frank Rauchfuß and Stefan Trebbin.  

    The Munich-based deep tech startup DXI GmbH has received strong funding in a pre-seed financing round. Investors include the High-Tech Gründerfonds (HTGF) as well as several renowned business angels from the AI and SaaS sectors. The VentureCon networking event organized by BayStartUP brought the founding team and investors together. With the fresh capital, DXI plans to further develop its AI platform PersonaX®, which enables companies for the first time to engage in dialogue with dynamic, adaptive “Digital Customer Twins” at any time. These Customer Twins can support in conducting A/B tests,  develop marketing campaigns, or optimize sales and support processes – in real time and based on deep customer insights. In doing so, it anticipates customer reactions, reflects authentic user behavior, and helps companies make decisions consistently from the customer’s perspective. The DXI team is pursuing a radical change in perspective: true customer centricity means consistently thinking and acting from the customer’s point of view. What if the customer could develop go-to-market measures, product ideas, or user-specific operating instructions themselves? It’s possible with digital technology, and that’s where DXI comes in with PersonaX®. 

    “We wanted to keep customer knowledge available at all times and make it accessible for dialogue so that it can be used realistically in digital applications and scaled easily,” says Stefan Trebbin, co-founder and CAIO (Chief AI Officer) of DXI GmbH.  

    The solution: a digital customer twin that not only observes but also actively shapes the process. PersonaX® takes on real use cases, generates deep customer insights in real time, and can take on assigned tasks—for example, as an “AI advisor” in product development, marketing, or customer success. Based on the proprietary AI Latent Insights Amplifier (LIA) platform, leading AI technologies are combined with an excellent user experience, enabling companies to make decisions from the customer’s perspective – at any time, based on data, and with empathy. “Thanks to its proprietary LIA technology, PersonaX® delivers models that are up to 20 times more efficient with over 90% accuracy – a technological quantum leap compared to conventional simulation tools,” explains Stefan Trebbin.  

    In addition to digital customer twins, PersonaX® also maps expert twins and enables the automation of entire processes in B2B and B2C application areas – from innovation management to CRM and customer support.  

    “Our vision is to use PersonaX® to create lifelike, adaptive B2B and B2C customer twins that enable companies not only to better understand customer expectations, but also to optimize their offerings and anticipate behavior,” says Frank Rauchfuß, co-founder and CEO of DXI GmbH. “By using digital customer twins, we are able to reduce costs by more than 70% and reduce time-to-insight by 90%.”  

    from left Frank Rauchfuß and Stefan Trebbin, Founders of DXI (Photo: DXI)

    Johannes Dierkes, Investment Manager at HTGF, comments: “At DXI, a very well-connected, experienced, and technically knowledgeable founding team has found an attractive market. The possible applications of this solution are enormously diverse. We see great potential for DXI’s digital twins to become a must-have tool in a wide range of business areas.”  

    According to Gartner Inc., the market for digital customer twins is on the verge of a major transformation: within the next five to ten years, almost all companies are expected to use digital twins of their customers. As the recent winner of Startup of the Week 2025, the iF Design Award 2024 and the AI Paper Award from TU Dresden, DXI confirms its role as a technological innovation leader – also in a European comparison.  

    With this pre-seed financing, DXI plans to take the next step toward fully autonomous customer twins, setting new standards for digital customer dialogue with a unique comination of real-time capability, dialogue depth and technological maturity.  

    Dr. Carsten Rudolph, Managing Director at BayStartUP, comments: “The DXI team combines entrepreneurial experience with a clear eye for digital efficiency levers. Their solution has the potential to become the standard for data-driven optimization in companies – a real toolkit for the future of digital transformation. We are delighted to have HTGF on board as an experienced investor who will now play a key role in driving the growth of this promising start-up.”  

    About DXI GmbH 
    DXI GmbH was founded on October 1, 2024, in Munich and specializes in AI-driven customer twins. With its PersonaX® platform, the startup offers companies a revolutionary way to interact with digital representations of their customers on eye level – dynamically, realistically, and in real time. The company’s proprietary Latent Insight Amplifier (LIA) technology combines deep data analysis with intuitive UX and leading AI. In addition to customer twins, the platform also trains expert twins and automates complex business processes. DXI has been honored with the iF Design Award 2024, among other awards, and is one of the innovation leaders in the field of “digital customer twins.” Frank Rauchfuß and Stefan Trebbin are AI pioneers with experience from over 800 projects in the B2B/B2C sector. 

    Media contact 
    DXI GmbH 
    Frank Rauchfuß, CEO  
    Email: founder@dx-i.com 
    Website: www.dx-i.com 
    Taufkirchen near Munich, Germany 

    About HTGF – High-Tech Gründerfonds  
    HTGF is one of the leading and most active early-stage investors in Germany and Europe, financing start-ups in the fields of Deep Tech, Industrial Tech, Climate Tech, Digital Tech, Life Sciences and Chemistry. With its experienced investment team, HTGF supports start-ups in all phases of their development into international market leaders. HTGF invests in pre-seed and seed phases and can participate significantly in later-stage financing rounds. Across its funds, HTGF has over 2 billion euros under management. Since its inception in 2005, HTGF has financed more than 770 start-ups and achieved almost 200 successful exits.   
    Fund investors in the public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital as well as 45 companies and family offices.   
    For more information, please visit HTGF.de or follow us on LinkedIn.    

    Media contact  
    High-Tech Gründerfonds Management GmbH  
    Tobias Jacob, Senior Marketing & Communications Manager   
    T.: +49 228 – 82300 – 121 
    t.jacob@htgf.de    

  • Atmos Test Flight

    Atmos Test Flight

    ATMOS Space Cargo Conducts First Re-Entry Mission from Space early on its way to building a leading return logistics platform with its Innovative Return Capsule

    • ATMOS Space Cargo meets critical mission objectives during first flight of its PHOENIX 1 prototype, launched as part of SpaceX’s Bandwagon-3 mission.
    • ATMOS tested its innovative Inflatable Heat Shield technology early under realistic flight conditions, as part if its rapid prototyping approach.
    • This mission marks a significant step forward to efficient and sovereign European return capacities.
    • PHOENIX 2 development is underway, with a test flight planned for 2026.

    A European Milestone in Re-Entry Technology

    This flight establishes ATMOS as the fastest-moving private space logistics company in Europe to conduct an orbital return mission. It also demonstrates that sovereign return capabilities are within reach – and that private industry is ready to lead in building Europe’s independent space infrastructure.

    “PHOENIX 1 delivered on its objectives and our roadmap. Dedicated people show up, go to work and get results – we are not here to guess. Completing this mission with a flight-ready capsule in such a short time frame is a major validation of our design and approach under real conditions,” said Sebastian Klaus, CEO and Co-Founder of ATMOS.

    “As a side effect it gave proof that we are able to conduct a multinational operation to create a valuable and inspiring outcome across the entire team and beyond.  We’re on track to build PHOENIX 2 – a next gen capsule capable of setting its own return trajectory, unlocking the most flexible, cost-efficient and reliable end-to-end space logistics platform in the space industry.”

    Mission Summary

    Launch & De-Orbit Maneuver

    PHOENIX 1 launched into space aboard a SpaceX Falcon 9 rocket from Launch Complex 40 (SLC-40), Cape Canaveral Space Force Station, Florida at 20:48 local time, as part of the Bandwagon-3 rideshare mission.

    Following injection into a 45° inclination orbit, the capsule completed one full orbit.

    A planned de-orbit burn by the Falcon 9 upper stage over Los Angeles, California, then placed PHOENIX 1 on its return trajectory.

    Re-entry & Data Recovery

    Following upper stage separation, PHOENIX 1 began its return trajectory, transmitting critical system and payload data to ground stations the ATMOS ground segment team set up across South America.

    As planned, the capsule performed initial inflation of its heat shield before entering Earth’s atmosphere at the Entry Interface Point (EIP) approximately two hours post-launch south-east of the Brazilian coast.

    Due to a recent trajectory update and extended splashdown distance (~2,000 km off the coast), recovery was not planned – effected by the increased distance from  available marine infrastructure.

    ATMOS’ current roadmap for PHOENIX 2 confirms to feature its own propulsion system, enabling the capsule to choose its re-entry trajectory and splashdown zone, enabling swift recovery.

    We designed PHOENIX 1 to move fast without compromising core reliability, fundamental for any spacecraft. Thanks to the experience and fast problem solving skill set our team brings to the workshop, we achieved flight qualification in record time. Building and launching a space-ready capsule in under a year required tight iteration and testing, good communication, and a team spirit beyond expectations. This flight – and the engineering process that led us here – taught us valuable lessons on the design of the next iteration, PHOENIX 2” says Christian Grimm, Lead Systems Engineer and Co-Founder at ATMOS Space Cargo.

    Christian Ziach, Principal at HTGF and board member at ATMOS, commented: “Watching the launch of the first demonstration flight of Atmos Space Cargo live in Cape Canaveral, seeing how the spacecraft is separated and then looking at the first telemetry data was pure goosebumps. Congratulations to the entire team of Atmos Space Cargo. You have done a great job!”


    About ATMOS Space Cargo
    ATMOS Space Cargo GmbH develops cutting-edge technology to enable the return of cargo from space. Its services encompass microgravity experiments, commercial payloads and support for spacecraft reusability. ATMOS bridges the gap between Earth and low Earth orbit, driving industrial innovation with sustainable solutions.

    The PHOENIX capsule represents a groundbreaking platform for Earth-to-Space-to-Earth logistics, designed for a wide variety of applications.

    About HTGF – High-Tech Gründerfonds 
    HTGF is one of the leading and most active early-stage investors in Germany and Europe, financing start-ups in the fields of Deep Tech, Industrial Tech, Climate Tech, Digital Tech, Life Sciences and Chemistry. With its experienced investment team, HTGF supports start-ups in all phases of their development into international market leaders. HTGF invests in pre-seed and seed phases and can participate significantly in later-stage financing rounds. Across its funds, HTGF has over 2 billion euros under management. Since its inception in 2005, HTGF has financed more than 770 start-ups and achieved almost 200 successful exits.  
    Fund investors in the public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital as well as 45 companies and family offices.  
    For more information, please visit HTGF.de or follow us on LinkedIn.   

    Media contact 
    High-Tech Gründerfonds Management GmbH 
    Tobias Jacob, Senior Marketing & Communications Manager  
    T.: +49 228 – 82300 – 121
    t.jacob@htgf.de